Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 20 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patientsRoss, D.; O'Hely, M.; Bartley, P.; Dang, P.; Score, J.; Goyne, J.; Sobrinho-Simoes, M.; Cross, N.; Melo, J.; Speed, T.; Hughes, T.; Morley, A.
2010Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Bartley, P.; Slader, C.; Field, C.; Dang, P.; Filshie, R.; Mills, A.; Grigg, A.; Vaz de Melo, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2014The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmentBranford, S.; Yeung, D.; Ross, D.; Parker, W.; Braley, J.; Seymour, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2011Do we have to kill the last CML cell?Ross, D.; Hughes, T.; Vaz de Melo, J.
2010Towards DNA-based monitoring of therapy in chronic myeloid leukemiaMorley, A.; Bartley, P.; Ross, D.; Latham, S.; Budgen, B.; Branford, S.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
2010Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNABartley, P.; Ross, D.; Latham, S.; Martin-Harris, M.; Budgen, B.; Wilczek, V.; Branford, S.; Hughes, T.; Morley, A.